What Is PT-141?

Overview

PT-141, also known by the nonproprietary name bremelanotide, is a synthetic cyclic heptapeptide that activates the melanocortin receptor system. It originated as a metabolite of an earlier tanning peptide and was subsequently developed in its own right because it appeared to influence behavioral pathways in the central nervous system. What sets it apart from vasodilator-type compounds is its proposed mechanism: rather than acting on local blood flow, it engages signaling circuits in the brain. It is the basis of an FDA-approved injectable indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women, which makes it unusually well documented for a peptide of its class.

How PT-141 Works

The peptide binds to several members of the melanocortin receptor family, with the centrally expressed MC3R and MC4R subtypes generally regarded as the most relevant to its studied effects. By agonizing these receptors in the central nervous system, it is thought to modulate neural pathways tied to arousal and desire — a route distinct from phosphodiesterase-5 inhibitors such as sildenafil, which act peripherally on penile blood flow. Notably, even in the regulatory labeling the precise mechanism by which the compound exerts its effect remains formally described as not fully understood, so much of the literature frames it in terms of melanocortin signaling rather than a single confirmed pathway.

What the Research Explores

• Central melanocortin signaling through the MC3R and MC4R receptor subtypes.
• Sexual-desire and arousal pathways in premenopausal-female models of hypoactive sexual desire disorder.
• On-demand, episodic dosing patterns versus fixed daily administration schedules.
• Broader melanocortin-system roles spanning sexual function and energy-balance regulation.

Forms & Handling

PT-141 is typically supplied as a lyophilized powder, commonly in a 10 mg vial. For laboratory work it is reconstituted with bacteriostatic water; adding roughly 3.0 mL to a 10 mg vial yields a concentration near 3.33 mg/mL (about 3,333 mcg/mL). Sealed lyophilized vials are stored cool, and once in solution the reconstituted material is kept refrigerated. Reference figures in the literature center on single amounts in the 500–1750 mcg range, with 1.75 mg being the approved fixed subcutaneous dose. See the dosing protocol below for the reconstitution math expressed in insulin-syringe units.

Safety & Research Notes

Outside its single approved clinical indication, PT-141 is handled as an investigational research compound with no established safety profile for general use. Even the approved labeling limits administration to no more than one dose in any 24-hour window and eight doses per month, and it is not indicated for men, postmenopausal women, or performance enhancement. Anything described here is mechanistic and historical background, not a usage recommendation.

References

Related Protocols